Evidence map›Paper›PMID 29719814›Full record

ArticleRespiratory medicine case reports2018

Transformation to small cell lung cancer after first-line afatinib treatment.

Takayuki Shiroyama, Shingo Nasu, Ayako Tanaka, So Takata, Kentaro Masuhiro, Hiromune Takada, Satomu Morita, Naoko Morishita, Hidekazu Suzuki, Norio Okamoto and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Understanding the Mechanisms of Resistance inInternational journal of molecular sciences · 2019
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Takayuki ShiroyamaDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Shingo NasuDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Ayako TanakaDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
So TakataDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Kentaro MasuhiroDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Hiromune TakadaDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Satomu MoritaDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Naoko MorishitaDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Hidekazu SuzukiDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Norio OkamotoDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Kunimitsu KawaharaDepartment of Pathology, Osaka Habikino Medical Center, Osaka, Japan.
Tomonori HirashimaDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acquiring resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is inevitable. Transformation to small cell lung cancer (SCLC) is reported as a possible mechanism of this acquired resistance. We describe the case of a 35-year-old man with lung adenocarcinoma harboring

Indexed as

Acquired resistanceAdenocarcinomaAfatinibRebiopsySmall cell lung cancerTransformation

Identifiers

PMID29719814
PMCPMC5925950

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.